JP2024505018A - ナルトレキソン組成物 - Google Patents

ナルトレキソン組成物 Download PDF

Info

Publication number
JP2024505018A
JP2024505018A JP2023544779A JP2023544779A JP2024505018A JP 2024505018 A JP2024505018 A JP 2024505018A JP 2023544779 A JP2023544779 A JP 2023544779A JP 2023544779 A JP2023544779 A JP 2023544779A JP 2024505018 A JP2024505018 A JP 2024505018A
Authority
JP
Japan
Prior art keywords
single unit
pharmaceutical composition
formulation
active ingredient
naltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505018A5 (https=
JPWO2022157385A5 (https=
Inventor
フード，フランソワ
Original Assignee
エルディーエヌ ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルディーエヌ ファーマ リミテッド filed Critical エルディーエヌ ファーマ リミテッド
Publication of JP2024505018A publication Critical patent/JP2024505018A/ja
Publication of JP2024505018A5 publication Critical patent/JP2024505018A5/ja
Publication of JPWO2022157385A5 publication Critical patent/JPWO2022157385A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023544779A 2021-01-25 2022-01-25 ナルトレキソン組成物 Pending JP2024505018A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21153332 2021-01-25
EP21153332.8 2021-01-25
PCT/EP2022/051619 WO2022157385A1 (en) 2021-01-25 2022-01-25 Naltrexone compositions

Publications (3)

Publication Number Publication Date
JP2024505018A true JP2024505018A (ja) 2024-02-02
JP2024505018A5 JP2024505018A5 (https=) 2025-01-20
JPWO2022157385A5 JPWO2022157385A5 (https=) 2025-01-20

Family

ID=74236099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544779A Pending JP2024505018A (ja) 2021-01-25 2022-01-25 ナルトレキソン組成物

Country Status (9)

Country Link
US (1) US20240108583A1 (https=)
EP (1) EP4281046B1 (https=)
JP (1) JP2024505018A (https=)
KR (1) KR20230136180A (https=)
CN (1) CN117545472A (https=)
AU (1) AU2022211609A1 (https=)
CA (1) CA3207647A1 (https=)
IL (1) IL304652A (https=)
WO (1) WO2022157385A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022103638A1 (en) * 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
GB202109018D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Treatment with an agonist of a 5-hydroxytryptamine (5-ht) receptor

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363068A (ja) * 2001-05-15 2002-12-18 Peirce Management Llc 口内と経口との両方の投与のための薬剤合成物並びにその調合方法及び投与方法
WO2007036802A2 (en) * 2005-07-07 2007-04-05 Teva Pharmaceutical Industries Limited Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
WO2008127669A1 (en) * 2007-04-11 2008-10-23 Cephalon, Inc. Bilayer lyophilized pharmaceutical compositions and methods of making and using same
JP2013522184A (ja) * 2010-03-12 2013-06-13 ジーダブリュー・ファーマ・リミテッド がんの治療におけるフィトカンナビノイド
JP2016524602A (ja) * 2013-05-10 2016-08-18 キャンサー ワクチン インスティテュート ナルトレキソンを用いたがんの処置
WO2019096853A1 (en) * 2017-11-14 2019-05-23 LDN Pharma Limited Cancer Treatment
WO2019186207A1 (en) * 2018-03-29 2019-10-03 LDN Pharma Limited Autoimmune therapy
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
WO2020188577A1 (en) * 2019-03-21 2020-09-24 Alvit Lcs Pharma Ltd. Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205081B2 (en) * 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US20140371210A1 (en) * 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
BR112017018316A2 (pt) * 2015-02-27 2018-04-17 Ebbu Llc composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
JP6968184B2 (ja) * 2016-10-25 2021-11-17 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 速崩壊多層錠のための異なる密度の組成物
US10517834B2 (en) * 2017-05-16 2019-12-31 Owen Murray Fast dissolving tablet formulations and methods of making thereof
CN109316454B (zh) * 2018-11-26 2021-06-15 正大制药（青岛）有限公司 一种骨化三醇制剂
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002363068A (ja) * 2001-05-15 2002-12-18 Peirce Management Llc 口内と経口との両方の投与のための薬剤合成物並びにその調合方法及び投与方法
WO2007036802A2 (en) * 2005-07-07 2007-04-05 Teva Pharmaceutical Industries Limited Sublingual dosage form comrising vitamin d analogue, in particular calcitriol
WO2008127669A1 (en) * 2007-04-11 2008-10-23 Cephalon, Inc. Bilayer lyophilized pharmaceutical compositions and methods of making and using same
JP2013522184A (ja) * 2010-03-12 2013-06-13 ジーダブリュー・ファーマ・リミテッド がんの治療におけるフィトカンナビノイド
JP2016524602A (ja) * 2013-05-10 2016-08-18 キャンサー ワクチン インスティテュート ナルトレキソンを用いたがんの処置
WO2019096853A1 (en) * 2017-11-14 2019-05-23 LDN Pharma Limited Cancer Treatment
WO2019186207A1 (en) * 2018-03-29 2019-10-03 LDN Pharma Limited Autoimmune therapy
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
WO2020188577A1 (en) * 2019-03-21 2020-09-24 Alvit Lcs Pharma Ltd. Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases

Also Published As

Publication number Publication date
CA3207647A1 (en) 2022-07-28
AU2022211609A1 (en) 2023-07-27
EP4281046B1 (en) 2025-09-10
KR20230136180A (ko) 2023-09-26
IL304652A (en) 2023-09-01
WO2022157385A1 (en) 2022-07-28
EP4281046A1 (en) 2023-11-29
AU2022211609A9 (en) 2025-03-13
US20240108583A1 (en) 2024-04-04
CN117545472A (zh) 2024-02-09
EP4281046C0 (en) 2025-09-10

Similar Documents

Publication Publication Date Title
CN112770726B (zh) 大麻素的缓释配方
RU2485949C2 (ru) Таблетка мелатонина и способы изготовления и применения
US20210322368A1 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
RU2487703C2 (ru) Фармацевтические композиции, включающие модулятор s1р
JP2004506680A (ja) シクロオキシゲナーゼ−２阻害剤の迅速崩壊経口製剤
TW200539902A (en) Oral pharmaceutical compositions of timed-release particles and tablets quickly disintegrable in the oral cavity containing compositions thereof
TW201247240A (en) Rapid dissolve tablet compositions for vaginal administration
JP2024505018A (ja) ナルトレキソン組成物
BRPI0610634A2 (pt) combinação para a terapia de hiperplasia benigna da próstata
EP4358943A1 (en) Naltrexone for boosting the therapeutic utility of 5-ht receptor agonists
ES2547138T3 (es) Composiciones que se disgregan por vía oral
US20180344648A1 (en) Clobazam tablet formulation and process for its preparation
JPWO2017146052A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
JP2009530284A (ja) 拡張期心不全を治療するための方法と組成物
TW202604474A (zh) 奈必洛爾與氨氯地平組合物、其製備方法及用途
CN121925252A (zh) 用于口服给药的含有卡巴他赛和脂质的组合物
Saha Immediate release drug delivery systems: a current update
EP3673901A1 (en) Pharmaceutical composition particles, orally disintegrating preparation containing same, and method for producing pharmaceutical composition particles
WO2006028362A1 (es) Composición farmacéutica de liberación prolongada de hidralazina y su uso como apoyo para el tratamiento del cáncer
HK1228298A1 (en) Pharmaceutical compositions comprising an s1p modulator
HK1262724A1 (zh) 透粘膜给药的药物组合物
TWM531276U (zh) 靈樟芝顆粒結構

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250108

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420